Barclays PLC Buys 45,797 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC)

Barclays PLC grew its stake in Century Therapeutics, Inc. (NASDAQ:IPSC) by 283.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,945 shares of the company’s stock after acquiring an additional 45,797 shares during the period. Barclays PLC’s holdings in Century Therapeutics were worth $106,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its stake in Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Century Therapeutics in the 3rd quarter worth approximately $27,000. Rhumbline Advisers lifted its position in shares of Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after purchasing an additional 18,828 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Century Therapeutics by 141.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares during the period. Finally, State Street Corp lifted its position in shares of Century Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares during the period. 50.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IPSC shares. HC Wainwright lowered their price target on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Chardan Capital lowered their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Piper Sandler lowered their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research report on Monday, December 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Century Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Stock Up 0.9 %

NASDAQ:IPSC opened at $1.07 on Thursday. The firm has a 50 day moving average of $1.26 and a 200 day moving average of $1.67. The stock has a market capitalization of $90.98 million, a price-to-earnings ratio of -0.58 and a beta of 1.76. Century Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The business had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same quarter last year, the company posted ($0.55) earnings per share. As a group, analysts expect that Century Therapeutics, Inc. will post -1.63 EPS for the current year.

Century Therapeutics Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.